Cancer cell CCR2 orchestrates suppression of the adaptive immune response

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• C-C chemokine receptor type 2 (CCR2) is primarily known for monocyte recruitment to tumors.
• The role of CCR2 within cancer cells, particularly breast cancer, remains largely undefined.
• Understanding cancer cell-intrinsic functions of CCR2 is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the functional role of C-C chemokine receptor type 2 (CCR2) in breast cancer cells.
• To determine the impact of CCR2 signaling in cancer cells on anti-tumor immunity and tumor progression.
• To explore therapeutic potential of targeting CCR2 in breast cancer.

Main Methods:

• Utilized an orthotopic, isograft breast cancer mouse model with Ccr2 deletion in cancer cells.
• Analyzed immune cell infiltration and activation, including cytotoxic T lymphocytes (CTLs) and CD103+ dendritic cells (DCs).
• Assessed changes in cancer cell expression of MHC class I and PD-L1.
• Investigated the effects of pharmacological and genetic CCR2 targeting on cancer cell sensitivity to CTLs and DC maturation.

Main Results:

• Ccr2 deletion in breast cancer cells significantly reduced tumor growth and doubled survival rates.
• Cancer cell-specific Ccr2 deletion enhanced infiltration and activation of CTLs and CD103+ cross-presenting DCs.
• Targeting CCR2 modulated cancer cell surface molecules, up-regulating MHC class I and down-regulating PD-L1.
• CCR2 inhibition sensitized cancer cells to CTL-mediated killing and promoted DC maturation.

Conclusions:

• CCR2 signaling within cancer cells actively suppresses the anti-tumor immune response.
• Targeting CCR2 in breast cancer cells can reprogram the tumor microenvironment to enhance anti-tumor immunity.
• CCR2 represents a promising therapeutic target for improving breast cancer treatment outcomes by modulating immune surveillance.